Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Zhang LN, Karp P, Gerard CJ, Pastor E, Laux D, Munson K, Yan Z, Liu X, Godwin S, Thomas CP, Zabner J, Shi H, Caldwell CW, Peluso R, Carter B, Engelhardt JF.
Zhang LN, et al.
Mol Ther. 2004 Dec;10(6):990-1002. doi: 10.1016/j.ymthe.2004.08.009.
Mol Ther. 2004.
PMID: 15564131
Free article.
Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated l …
Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dr …